NCT03020303

Brief Summary

Individuals receiving dialysis are at risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in patients that require dialysis. Spironolactone is a pill used to prevent heart failure and related deaths in patients that do not require dialysis. It works by blocking a hormone (aldosterone) in your body that causes high blood pressure and can damage the heart. Although spironolactone is very effective in patients that do not require dialysis, we do not know if spironolactone is effective in dialysis patients. Our research will help determine if spironolactone reduces heart failure and heart related deaths in dialysis patients. The purpose of this study is to determine if spironolactone reduces death or hospitalization for heart failure and is well tolerated in patients that require dialysis.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
2,538

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Jul 2017

Longer than P75 for phase_3

Geographic Reach
12 countries

141 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 11, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 13, 2017

Completed
6 months until next milestone

Study Start

First participant enrolled

July 7, 2017

Completed
7.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 14, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 14, 2025

Completed
Last Updated

March 20, 2025

Status Verified

March 1, 2025

Enrollment Period

7.7 years

First QC Date

January 11, 2017

Last Update Submit

March 17, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • CV Death or Hospitalization for Heart Failure

    up to 5 years

Secondary Outcomes (5)

  • Cause specific death

    up to 5 years

  • Hospitalization for Heart Failure

    up to 5 years

  • All-cause death

    up to 5 years

  • All-cause Hospitalization

    up to 5 years

  • Hospitalization for hyperkalemia

    up to 5 years

Study Arms (2)

Placebo Oral Tablet

PLACEBO COMPARATOR

A tablet with no active medication that will be an exact match of the active spironolactone in taste and appearance

Drug: Placebo Oral Tablet

Spironolactone 25 MG Tablet

ACTIVE COMPARATOR

25 mg of active spironolactone in tablet form

Drug: Spironolactone 25Mg Tablet

Interventions

Randomized participants will receive a study supply of spironolactone 25 mg tablets. They will be instructed to take 1 tablet daily.

Spironolactone 25 MG Tablet

Randomized participants will receive a study supply of placebo tablets with no active medical ingredients. They will be instructed to take 1 tablet daily.

Placebo Oral Tablet

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age
  • ≥45 years or
  • ≥18 with a history of diabetes
  • On dialysis ≥ 90 days
  • On either
  • Hemodialysis prescribed at least 2 treatments per week or
  • Peritoneal dialysis prescribed with at least 1 exchange daily
  • Provides informed consent

You may not qualify if:

  • Hyperkalemia
  • Serum potassium \>5.8 mmol/L in the 6 weeks prior to enrollment or
  • Serum potassium \>6.0 mmol/L during active run-in
  • Currently taking and unable to withdraw a mineralocorticoid receptor antagonist (i.e. spironolactone or eplerenone).
  • Known sensitivity or allergy to spironolactone
  • Current or planned pregnancy or breastfeeding
  • Scheduled living related donor renal transplant
  • Life expectancy \< 6 months in the opinion of a treating nephrologist.
  • Enrolled in another interventional trial testing a mineralocorticoid receptor antagonist or drug that has a known or likely interaction with spironolactone.
  • Treating physician believes either spironolactone is either absolutely indicated or absolutely contra-indicated

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (141)

Canberra Hospital

Garran, Australian Capital Territory, 2605, Australia

Location

Concord Repatriation General Hospital

Concord, New South Wales, 2139, Australia

Location

Northern Beaches Hospital

Frenchs Forest, New South Wales, 2086, Australia

Location

Royal North Shore Hospital

Wahroonga, New South Wales, 2076, Australia

Location

Sydney Adventist Hospital

Wahroonga, New South Wales, 2076, Australia

Location

Sunshine Coast University Hospital

Birtinya, Queensland, 4575, Australia

Location

Royal Brisbane Women&#39;s Hospital

Herston, Queensland, 4029, Australia

Location

Princess Alexandra Hospital

Woolloongabba, Queensland, 4102, Australia

Location

Monash Health

Clayton, Victoria, 3168, Australia

Location

Western Health - Sunshine Hospital

Saint Albans, Victoria, 3021, Australia

Location

Santa Casa de Misericordia de Belo Horizonte

Santa Efigênia, Belo Horizonte, 30150221, Brazil

Location

Medical School of Botucatu of the Paulista State University - UNESP

Rubião Júnior, Botucatu, 18618-687, Brazil

Location

Fundacao Pro-Rim

Boa Vista, Joinville, 89227680, Brazil

Location

Felicio Rocho Foundation - Hospital Felicio Rocho

Belo Horizonte, Minas Gerais, 30110934, Brazil

Location

Fundacao Hospitalar Sao Francisco de Assis

Belo Horizonte, Minas Gerais, 31110580, Brazil

Location

Servico Ubaense de Nefrologia Ltda

Ubá, Minas Gerais, 36500008, Brazil

Location

Sociedade Hospitalar Angelina Caron

Campina Grande do Sul, Paraná, 83430000, Brazil

Location

Instituto Pro Renal Brazil

Curitiba, Paraná, 80440-020, Brazil

Location

Irmandade da Santa Casa de Misericordia de Porto Alegre -ISCMPA

Bairro Santa Teresa, Porto Alegre, 90020090, Brazil

Location

Hospital de Clinicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

Location

Hospital Arquidiocesano Consul Carlos Reneaux

Brusque, Santa Catarina, 8835404, Brazil

Location

PROCARDIO Clinica Cardiologica

Blumenau, South Carolina, 89010500, Brazil

Location

Praxis Pesquisa Medica S/S

Santo André, São Paulo, 09090 790, Brazil

Location

Santa Casa de Misericordia de Votuporanga

Votuporanga, São Paulo, 15500003, Brazil

Location

Hospital Alemao Oswaldo Cruz

Bela Vista, Brazil

Location

Santa Casa de Misericordia de Ponta Grossa

Ponta Grossa, Brazil

Location

Foothills Hospital

Calgary, Alberta, T2N 2T9, Canada

Location

University of Alberta

Edmonton, Alberta, T6G 2G3, Canada

Location

Royal Inland Hospital

Kamloops, British Colombia, V2C 2T1, Canada

Location

Kelowna General Hospital

Kelowna, British Colombia, V1Y 1T2, Canada

Location

St. Pauls Hospital

Vancouver, British Colombia, V6Z 1Y6, Canada

Location

Penticton Regional Hospital

Penticton, British Columbia, Canada

Location

Queen Elizabeth II Health Science Centre

Halifax, Nova Scotia, B3H 1V7, Canada

Location

Cape Breton Regional Hospital

Sydney, Nova Scotia, Canada

Location

Health Sciences North Research Institute

Greater Sudbury, Ontario, P3E 5J1, Canada

Location

St. Joseph's Healthcare

Hamilton, Ontario, L8N 4A6, Canada

Location

Queens University at Kingston General Hospital, Division of Nephrology

Kingston, Ontario, Canada

Location

Victoria Hospital

London, Ontario, N6A 5W9, Canada

Location

Ottawa Hospital Research Institute

Ottawa, Ontario, K1Y 4E9, Canada

Location

St. Michael's Hospital

Toronto, Ontario, M5B 1W8, Canada

Location

St. Josephs, Toronto

Toronto, Ontario, M6R 1B5, Canada

Location

Humber River Health

Toronto, Ontario, Canada

Location

CIUSSS Hopital Maisonneuve- Rosemont

Montreal, Quebec, H1T 2M4, Canada

Location

Centre Hospitalier de l&#39;Universite de Montreal (CHUM)

Montreal, Quebec, H2W 1T8, Canada

Location

Hopital du Sacre-Coeur de Montreal

Montreal, Quebec, H4J 1C5, Canada

Location

The Sir Mortimer B. Davis Jewish General Hospital

Montreal, Quebec, Canada

Location

CHU de Quebec L'Hotel-Dieu de Quebec

Québec, Quebec, G1R 2J6, Canada

Location

Peking University First Hospital

Beijing, Beijing Municipality, China

Location

Peking University Peoples Hospital

Beijing, Beijing Municipality, China

Location

General Hospital of Ningxia Medical University

Yinchuan, Ningxia, China

Location

The First Affiliated Hospital of Baotou Medical College

Baotou, China

Location

Beijing Miyun District Hospital

Beijing, China

Location

Beijing Tongren Hospital, Capital Medical University

Beijing, China

Location

Emergency General Hospital

Beijing, China

Location

Faw General Hospital of Jilin Province

Changchun, China

Location

The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture

Enshi, China

Location

Huai'an First Peoples Hospital

Huai'an, China

Location

The First Hospital of Kunming

Kunming, China

Location

Gansu Baoshihua Hospital

Lanzhou, China

Location

Yichuan County Traditional Chinese Medicine Hospital

Luoyang, China

Location

Shanghai Tongji Hospital

Shanghai, China

Location

Shanxi Provincial Peoples Hospital

Shanxi, China

Location

Shuyang County Hospital of Traditional Chinese Medicine

Suqian, China

Location

Sihong County Fenjinting Hospital

Suqian, China

Location

Tianjin Fifth Central Hospital

Tianjin, China

Location

Tianjin Third Central Hospital

Tianjin, China

Location

Tongiao City Hospital

Tongliao, China

Location

Xinxiang First Peoples Hospital

Xinxiang, China

Location

General Hospital of Xuzhou Mining Group

Xuzhou, China

Location

Peoples Hospital of Yuxi City

Yuxi, China

Location

Peoples Hospital of Zhongwei

Zhongwei, China

Location

Clinefnorte CIA Ltda

Quito, Pichincha, 170303, Ecuador

Location

Nefromedic SA

Quito, Pichincha, 170601, Ecuador

Location

Madras Medical College Chennai

Park Town, Chennai, 600003, India

Location

Narayana Hrudayalaya Limited

Bangalore, Karnataka, 560099, India

Location

Fortis Hospitals

Bengaluru, Karnataka, 560076, India

Location

K S Hegde Medical Academy

Mangaluru, Karnataka, 575018, India

Location

Nanjappa Hospitals Shimoga

Shimoga, Karnataka, 577201, India

Location

AsterMedCity

Kochi, Kerala, 682027, India

Location

Caritas Hospital

Kottayam, Kerala, 686630, India

Location

AIMS Hospital Mumbai

Dombivali, Maharashtra, 421203, India

Location

National Health and Education Society

Mumbai, Maharashtra, 400016, India

Location

Ashirwad Hospital Mumbai

Mumbai, Maharashtra, 421004, India

Location

Dhadiwal Hospital

Nashik, Maharashtra, 422002, India

Location

ACE Hospital Une

Pune, Maharashtra, 411004, India

Location

Aditya Birla Hospital

Pune, Maharashtra, 411033, India

Location

Vijaya Hospital

Chennai, Tamil Nadu, 600026, India

Location

Apollo Hospitals

Chennai, Tamil Nadu, 600081, India

Location

Nizams Institute of Medical Sciences

Hyderabad, Telangana, 500082, India

Location

Osmania General Hospital

Hyderabad, Telegana, 500012, India

Location

Government Rajaji Hospital, Madurai

Madurai, India

Location

Father Muller Medical College

Mangalore, India

Location

Seven Star Hospital

Nagpur, India

Location

Hospital Sultanah Aminah, Johor Bahru

Johor Bahru, Johor, 80100, Malaysia

Location

Hospital Pakar Sultanah Fatimah

Muar town, Johor, Malaysia

Location

Hospital Kuala Lumpur

Kuala Lumpur, Kuala Lumpur, 42896, Malaysia

Location

University Malaya Medical Centre (UMMC)

Kuala Lumpur, Kuala Lumpur, 59100, Malaysia

Location

Hospital Sultanah Nur Zahirah Kuala Terengganu

Kuala Terengganu, Kuala Terengganu, 33158, Malaysia

Location

Hospital Taiping

Taiping, Perak, 34000, Malaysia

Location

Hospital Pulau Pinang

George Town, Pulau Pinang, 10990, Malaysia

Location

Hospital Kajang

Kajang, Selangor, 43000, Malaysia

Location

Hospital Tengku Ampuan Rahimah Klang

Klang, Selangor, 41200, Malaysia

Location

Hospital Tengku Ampuan Afzan, Kuantan

Kuantan, 29142, Malaysia

Location

Hospital Tuanku Jaafar, Seremban

Seremban, 25167, Malaysia

Location

Hospital Ampang

Setapak, 53200, Malaysia

Location

North Shore Hospital

Takapuna, Auckland, 0620, New Zealand

Location

Waikato Hospital

Hamilton, Waikato Region, 3204, New Zealand

Location

Dunedin Hospital

Dunedin, 9016, New Zealand

Location

Hawkes Bay Hospital

Hastings, 4120, New Zealand

Location

Palmerston North Hospital

Palmerston North, 4442, New Zealand

Location

Whangarei Hospital

Whangarei, 0148, New Zealand

Location

Philippines General Hospital

Ermita, Manila, 1000, Philippines

Location

National Kidney and Transplant Institute

Quezon City, Manila, 1101, Philippines

Location

Hacettepe University Hospitals Hemodialysis Center

Ankara, Turkey (Türkiye)

Location

Osmangazi University

Eskişehir, Turkey (Türkiye)

Location

Memorial Service Hospital

Istanbul, Turkey (Türkiye)

Location

Ulster Hospital

Dundonald, Belfast, BT16 1RH, United Kingdom

Location

Southmead Hospital

Bristol, Bristol, BS10 5NB, United Kingdom

Location

University Hospital of Whales Health Park

Cardiff, Cardiff, CF14 4XW, United Kingdom

Location

Daisy Hill Hospital

Newry, Down, BT35 8DR, United Kingdom

Location

Queen Elizabeth University Hospital

Glasgow, Glasgow, G51 4TF, United Kingdom

Location

East Kent Canterbury Hospital

Canterbury, Kent, CT1 3NG, United Kingdom

Location

The Royal London Hospital

London, London, E1 2ES, United Kingdom

Location

Kings College Hospital

London, London, SE5 9RS, United Kingdom

Location

City Hospital

Nottingham, Nottingham, NG5 1PB, United Kingdom

Location

Churchill Hospital

Headington, Oxford, OX3 7LE, United Kingdom

Location

Salford Royal Hospital

Salford, Salford, M6 8HD, United Kingdom

Location

Aberdeen Royal Infirmary

Aberdeen, AB23 2ZN, United Kingdom

Location

Belfast City Hospital

Belfast, BT9 7AB, United Kingdom

Location

Birmingham Hospitals

Birmingham, United Kingdom

Location

Epsom St. Helier

Carshalton, United Kingdom

Location

Royal Derby Hospital

Derby, DE22 3NE, United Kingdom

Location

Ninewells Hospital

Dundee, DD1 9SY, United Kingdom

Location

Leicester General Hospital

Leicester, United Kingdom

Location

Liverpool University Hospitals

Liverpool, United Kingdom

Location

South Tees James Cook Hospital

Middlesbrough, United Kingdom

Location

Royal Stoke University Hospital

Stoke-on-Trent, United Kingdom

Location

Canimel Center

Melo, Departamento de Cerro Largo, Uruguay

Location

SEDIC Center

Montevideo, Montevideo Department, 11800, Uruguay

Location

Cedina Center

Montevideo, Uruguay

Location

Centro de Asistencia del Sindicato Medico del Uruguay-Institucion de Asistencia medica Privada (CASMU-IAMPP)

Montevideo, Uruguay

Location

Related Publications (8)

  • Quach K, Lvtvyn L, Baigent C, Bueti J, Garg AX, Hawley C, Haynes R, Manns B, Perkovic V, Rabbat CG, Wald R, Walsh M. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2016 Oct;68(4):591-598. doi: 10.1053/j.ajkd.2016.04.011. Epub 2016 Jun 3.

    PMID: 27265777BACKGROUND
  • Walsh M, Manns B, Garg AX, Bueti J, Rabbat C, Smyth A, Tyrwhitt J, Bosch J, Gao P, Devereaux PJ, Wald R. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial. Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1602-8. doi: 10.2215/CJN.12371214. Epub 2015 Jul 2.

    PMID: 26138259BACKGROUND
  • Walsh M, Collister D, Gallagher M, Mark PB, de Zoysa JR, Tyrwhitt J, Tennankore K, Reis G, Xavier D, Liu WJ, Zuo L, Wang AY, Felix C, Sola L, Arici M, Villanueva R, Jha V, Precoma D, Rabbat CG, Alavudeen SS, Faruqui AR, Lopez-Flecher M, Pyne L, Wald R, Yuan F, Balasubramanian K, Lee SF, Kuptsova A, Christou C, Devereaux PJ; ACHIEVE Investigators. Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial. Lancet. 2025 Aug 16;406(10504):695-704. doi: 10.1016/S0140-6736(25)01198-5.

  • Walsh M, Collister D, Gallagher M, Mark PB, de Zoysa JR, Tyrwhitt J, Tennankore K, Sola L, Reis G, Xavier D, Villanueva R, Liu WJ, Felix C, Zuo L, Arici M, Jha V, Wald R, Wang AY, Faruqui AR, Yuan F, Lee SF, Kuptsova A, Christou C, Devereaux PJ; ACHIEVE Investigators. The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol. Can J Kidney Health Dis. 2025 Jun 3;12:20543581251348187. doi: 10.1177/20543581251348187. eCollection 2025.

  • Huang B, McDowell G, Rao A, Lip GYH. Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit? J Hypertens. 2024 Mar 1;42(3):396-398. doi: 10.1097/HJH.0000000000003643. Epub 2024 Feb 1. No abstract available.

  • Soomro QH, Charytan DM. Mineralocorticoid Receptor Antagonists and Cardiovascular Health with Kidney Failure. Clin J Am Soc Nephrol. 2021 Jun;16(6):843-845. doi: 10.2215/CJN.04460421. No abstract available.

  • Collister D, Mbuagbaw L, Guyatt G, Devereaux PJ, Tennankore KK, Reis G, Sola L, Xavier D, Jha V, Gallagher M, Dans AL, Liu W, de Zoysa J, Felix C, Mark PB, Li Z, Tyrwhitt J, Wilkinson J, Sheridan P, Yuan F, Walsh M; ACHIEVE investigators. Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trial. Contemp Clin Trials. 2021 Aug;107:106466. doi: 10.1016/j.cct.2021.106466. Epub 2021 Jun 5.

  • Hasegawa T, Nishiwaki H, Ota E, Levack WM, Noma H. Aldosterone antagonists for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2021 Feb 15;2(2):CD013109. doi: 10.1002/14651858.CD013109.pub2.

MeSH Terms

Interventions

SpironolactoneTablets

Intervention Hierarchy (Ancestors)

LactonesOrganic ChemicalsPregnenesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsDosage FormsPharmaceutical Preparations

Study Officials

  • Michael Walsh, MD, PhD

    McMaster University

    PRINCIPAL INVESTIGATOR
  • PJ Devereaux, MD, PhD

    McMaster University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 11, 2017

First Posted

January 13, 2017

Study Start

July 7, 2017

Primary Completion

March 14, 2025

Study Completion

March 14, 2025

Last Updated

March 20, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

N/A - no plan to make IPD available to other researchers

Locations